CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-949-7530624
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
CombiMatrix (NASDAQ:CBMX) Frequently Asked Questions
What is CombiMatrix's stock symbol?
CombiMatrix trades on the NASDAQ under the ticker symbol "CBMX."
When did CombiMatrix's stock split? How did CombiMatrix's stock split work?
CombiMatrix's stock reverse split on the morning of Monday, February 1st 2016. The 1-15 reverse split was announced on Wednesday, January 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 29th 2016. An investor that had 100 shares of CombiMatrix stock prior to the reverse split would have 7 shares after the split.
How were CombiMatrix's earnings last quarter?
CombiMatrix Corp (NASDAQ:CBMX) posted its quarterly earnings results on Monday, November, 6th. The medical research company reported ($0.08) EPS for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.03. The medical research company had revenue of $4.01 million for the quarter, compared to the consensus estimate of $4.19 million. During the same quarter in the previous year, the business posted ($0.38) EPS. View CombiMatrix's Earnings History.
Has CombiMatrix been receiving favorable news coverage?
Press coverage about CBMX stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CombiMatrix earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for CombiMatrix.
What other stocks do shareholders of CombiMatrix own?
Who are CombiMatrix's key executives?
CombiMatrix's management team includes the folowing people:
- Robert Judd Jessup, Chairman of the Board (Age 68)
- Mark McDonough, President, Chief Executive Officer, Director (Age 46)
- Scott R. Burell, Chief Financial Officer, Treasurer, Secretary (Age 52)
- Dirk van den Boom Ph.D., Director (Age 47)
- Robert E. Hoffman, Independent Director (Age 51)
- Jeremy M. Jones, Independent Director (Age 75)
- Lale White, Independent Director (Age 60)
What is CombiMatrix's official website?
How can I contact CombiMatrix?
CombiMatrix's mailing address is 310 Goddard Ste 150, IRVINE, CA 92618-4617, United States. The medical research company can be reached via phone at +1-949-7530624.
MarketBeat Community Rating for CombiMatrix (NASDAQ CBMX)
MarketBeat's community ratings are surveys of what our community members think about CombiMatrix and other stocks. Vote "Outperform" if you believe CBMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
